

MIT Open Access Articles

Is antibacterial PNA the answer for combating multidrug resistant bacterial infections?

The MIT Faculty has made this article openly available. **Please share** how this access benefits you. Your story matters.

Citation: Ghosal, Anubrata. "Is Antibacterial PNA the Answer for Combating Multidrug Resistant Bacterial Infections?" International Journal of Biosciences (IJB) 10, no. 1 (January 31, 2017): 408-410.

As Published: <http://dx.doi.org/10.12692/ijb/10.1.408-410>

Publisher: International Network for Natural Sciences (INNSPUB)

Persistent URL: <http://hdl.handle.net/1721.1/107894>

Version: Final published version: final published article, as it appeared in a journal, conference proceedings, or other formally published context

Terms of Use: Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.





Is antibacterial PNA the answer for combating multidrug resistant bacterial infections?

Anubrata Ghosal

Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, United States

Key words: PNA, drug resistance bacteria, antibiotics.

<http://dx.doi.org/10.12692/ijb/10.1.408-410>

Article published on January 30, 2017

Abstract

The emergence of multidrug resistant bacterial infections is a serious problem. Treatment options are limited to patients those are infected with multidrug resistant bacteria. We are in a desperate need of new antibiotics. Antisense oligomers of PNA (Peptide Nucleic Acid) were introduced in late 90's as antibacterial agents in an intention to create a new class of bacterial specific antibiotic. Followed by several studies have demonstrated that antibacterial PNA oligomers are effective in a variety of pathogenic bacterial strains. Development of PNA-based drugs (PNA antibiotics) will help us to combat infections of drug resistant bacterial strains.

*Corresponding Author: Anubrata Ghosal ✉ anubrata@mit.edu

The number of multidrug resistant bacteria is increasing at an alarming rate. This is happening mainly due to the uncontrolled use of antibiotics and transfer of resistance genes within bacteria. The majority of previously discovered antibiotics are now not useful in eradicating multidrug resistant bacterial infections, although, in some cases, the combination of antibiotics still work. There are very few antibiotics such as ceftobiprole, linezolid, daptomycin, amikacin, etc. that are effective on multidrug resistant bacterial strains.

The number of deaths associated with multidrug resistant bacterial infections is increasing everywhere in the world, indicating that we are not too far to reach the post-antibiotic era. Since the discovery of penicillin, not many new classes of antibiotic were discovered (Lewis, 2013); although, in recent years, the initiatives of discovering new antibacterial drugs have increased steadily. The need of new kinds of antibiotic is paramount.

PNA oligomers were first introduced as antisense antibacterial agents in late 90's (Good and Nielsen, 1998). A few years later, it was shown that peptide conjugated PNA oligomers (antibacterial PNA) are capable of killing bacteria by inhibiting the function of *acpP* gene and provide protection from *E. coli* infection (Good *et al*, 2001). Thereafter, several studies have demonstrated the potential of antibacterial PNAs in inhibiting the growth of many human pathogenic bacteria (Ghosal, in press; Ghosal, 2012). Further, it was shown that antibacterial PNAs are capable of reducing bacterial load in infection mice models (Tan *et al*, 2005; Bai *et al*, 2012). Antibacterial PNAs also inhibit the growth of *Pseudomonas aeruginosa* (Ghosal and Nielsen, 2012), and anti-*acpP*PNAs are effective in inhibiting the growth of different strains of *Pseudomonas aeruginosa*. Furthermore, *Pseudomonas aeruginosa* LESB58 strain (a clinical isolate) showed sensitivity to lower doses of antibacterial PNAs compared to antibiotic ofloxacin and ceftazidime. A just-published study, which characterizes a *Pseudomonas* specific

antibacterial PNA, highlighted that antibacterial PNA is capable of reducing the production of pro-inflammatory cytokines in an *in vitro* cell culture infection model (Montagner *et al*, 2017).

The potency of antibacterial PNA molecules depends on the properties of conjugated peptide and the PNA oligomer. The conjugated peptide helps in transportation of PNA oligomer into the bacterial cytosol; inside the bacterial cytosol, antisense PNA oligomer binds to the target RNA. In some cases, conjugated peptides degrade in bacterial periplasm after crossing the outer membrane (Gram-negative bacteria), and from periplasm, PNA oligomers transport to cytoplasm by inner membrane transporters, while some peptides remain attached to the PNA oligomers after crossing the bacterial membrane (Ghosal *et al*, 2013).

Properties of antibacterial PNAs provide an advantage to design bacterial specific antibiotics. Designing of bacterial specific antibiotics is always advantageous as it lives other beneficial bacteria unharmed.

The human body is colonized by a vast number of microorganisms where majority of them are represented by bacteria (Bäckhed *et al*, 2005). Recently, it has shown that bacteria secrete RNA, and these secreted RNA have the potential to alter the behavior of host cells (Ghosal *et al*, 2015; Fritz *et al*, 2016; Koeppen *et al*, 2016). It would be relatively easy to design PNA-based inhibitors against those effector RNA molecules.

Despite several advantages, delivery of antibacterial PNA oligomers is still a challenge; it requires a vehicle to get into the bacterial cell. Several studies need to be done to take antibacterial PNAs to the clinics. Further, instead of using antibacterial PNA alone as an antibiotic, it would also be advantageous to use antibacterial PNA in combination with commonly used drugs where antibacterial PNA will be used to sensitize multidrug resistant bacteria to the drugs.

References

- Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI.** 2005. Host-bacterial mutualism in the human intestine. *Science*. **307**(5717), 1915–20.
<http://dx.doi.org/10.1126/science.1104816>
- Bai H, You Y, Yan H, Meng J, Xue X, Hou Z, Zhou Y, Ma X, Sang G, Luo X.** 2012. Antisense inhibition of gene expression and growth in gram-negative bacteria by cell-penetrating peptide conjugates of peptide nucleic acids targeted to *rpoD* gene. *Biomaterials*. **33**(2), 659–67.
- Fritz JV, Heintz-Buschart A, Ghosal A, Wampach L, Etheridge A, Galas D, Wilmes P.** 2016. Sources and Functions of Extracellular Small RNAs in Human Circulation. *Annu. Rev. Nutr.* **36**, 301–36.
<http://dx.doi.org/10.1146/annurev-nutr-071715-050711>
- Ghosal A.** Peptide nucleic acid opens an avenue of developing novel antibacterial molecules. *J. Infect. Dev. Ctries. in press*.
- Ghosal A.** 2012. Novel antibacterial agents (antibiotics) based on RNA interference using Peptide Nucleic Acid (PNA). University of Copenhagen.
<http://dx.doi.org/193097359>.
- Ghosal A, Nielsen PE.** 2012. Potent antibacterial antisense peptide–peptide nucleic acid conjugates against *Pseudomonas aeruginosa*. *Nucleic Acid Ther.* **22**(5), 323–34.
- Lewis K.** 2013. Platforms for antibiotic discovery. *Nat. Rev. Drug Discov* **12**(5), 371–87.
- Montagner G, Bezzerri V, Cabrini G, Fabbri E, Borgatti M, Lampronti I, Finotti A, Nielsen PE, Gambari R.** 2017. An antisense peptide nucleic acid against *Pseudomonas aeruginosa* inhibiting bacterial-induced inflammatory responses in the An
Montagner G, Bezzerri V, Cabrini G, Fabbri E, Borgatti M, Lampronti I, Finotti A, Nielsen
<http://dx.doi.org/10.1089/nat.2012.0370>
- Ghosal A, Vitali A, Stach JE, Nielsen PE.** 2013. Role of SbmA in the uptake of peptide nucleic acid (PNA)-peptide conjugates in *E. coli*. *ACS Chem. Biol.* **8**(2), 360–7.
<http://dx.doi.org/10.1021/cb300434e>
- Ghosal A, Upadhyaya BB, Fritz JV, Heintz-Buschart A, Desai MS, Yusuf D, Huang D, Baumuratov A, Wang K, Galas D, Wilmes P.** 2015. The extracellular RNA complement of *Escherichia coli*. *Microbiologyopen*. **4**(2), 252–266.
<http://dx.doi.org/10.1002/mb03.235>
- Good L, Nielsen PE.** 1998. Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. *Nat. Biotechnol.* **16**(4), 355–8.
<http://dx.doi.org/10.1038/nbt0498-355>
- Good L, Awasthi SK, Dryselius R, Larsson O, Nielsen PE.** 2001. Bactericidal antisense effects of peptide–PNA conjugates. *Nat. Biotechnol.* **19**(4), 360–364.
<http://dx.doi.org/10.1038/86753>
- Koeppen K, Hampton TH, Jarek M, Scharfe M, Gerber SA, Mielcarz DW, Demers EG, Dolben EL, Hammond JH, Hogan DA, Stanton BA.** 2016. A Novel Mechanism of Host-Pathogen Interaction through sRNA in Bacterial Outer Membrane Vesicles. *PLOS Pathog.* **12**(6), e1005672.
- PE, Gambari R.** 2017. antisense peptide nucleic acid against *Pseudomonas aeruginosa* inhibiting bacterial-induced inflammatory responses in the cystic fibrosis IB3-1 cellular model system. *Int. J. Biol. Macromol.* **S0141-8130(16)**, 30671–7
- Tan XX, Actor JK, Chen Y.** 2005. Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: proof of principle using mouse intraperitoneal infection. *Antimicrob Agents Chemother* **49**(8), 3203–7.